Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?

Kardiol Pol. 2023;81(10):1012-1014. doi: 10.33963/KP.a2023.0147. Epub 2023 Jul 4.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome* / drug therapy
  • Anticholesteremic Agents*
  • Cholesterol, LDL
  • Dyslipidemias*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Treatment Outcome

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Anticholesteremic Agents